---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-019249"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T13:45:31.396896+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics Q1 net loss $9.9M ($0.17/shr); cash runway through May 2023

## Summary
- Net loss of $9.9M for Q1 2022 vs $6.3M in Q1 2021; R&D spend rose to $8.1M (up from $4.9M) on NAVIGATE trial costs.
- Cash and equivalents $31.6M; company expects to fund operations through at least May 16, 2023.
- Expects to require additional $40-45M to reach planned interim analysis of NAVIGATE trial in mid-2024.
- Phase 2b/3 NAVIGATE trial enrollment for NASH cirrhosis on track to finish Phase 2b portion around Q3 2022.
- Company preparing IND to study belapectin in combination with Keytruda for recurrent head and neck cancer.

## SEC filing metadata
- accession: 0001140361-22-019249
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036122019249/0001140361-22-019249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036122019249/brhc10037527_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-019249
- JSON: https://secwatch.observer/filing/0001140361-22-019249.json
- Plain text: https://secwatch.observer/filing/0001140361-22-019249.txt

## Key facts
- Earnings Releases
  GALECTIN THERAPEUTICS INC reported the three months ended March 31, 2022 results: net income net loss applicable to common stockholders of $9.9 million, EPS ($0.17) per share.
  - Period: the three months ended March 31, 2022
  - Net income: net loss applicable to common stockholders of $9.9 million
  - EPS: ($0.17) per share
  - Result: reported results
  source text: For the three months ended March 31, 2022, the Company reported a net loss applicable to common stockholders of $9.9 million, or ($0.17) per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036122019249/0001140361-22-019249-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.